Literature DB >> 20459052

Pharmacokinetics and biodegradation mechanisms of a versatile carboxymethyl derivative of chitosan in rats: in vivo and in vitro evaluation.

Wen Dong1, Baoqing Han, Yilin Feng, Fulai Song, Jing Chang, Huiping Jiang, Yingying Tang, Wanshun Liu.   

Abstract

Carboxymethyl chitosan (CM-chitosan), which is a water-soluble derivative of chitosan, has attracted much attention as a new biomedical material. The safety study of this material was persuasive for its potential application. The present study was conducted to assess the tissue distribution, pharmacokinetics, biodegradation mechanism, and excretion of CM-chitosan in rats. After the rats were intraperitoneally injected at the dose of 50 mg/kg, the fluorescein isothiocyanate (FITC)-labeled CM-chitosan was absorbed rapidly and distributed to different organs, including liver, spleen, and kidney. The highest level of CM-chitosan was found in liver. It was at the level of 1.6 +/- 0.6 mg/liver and made up approximately 10-22% of the total injected FTC-CM-chitosan. Urinary excretion was the predominant way of excretion of FITC-labeled CM-chitosan, and 85% of the dose was excreted in urine over the period of 11 days. The molecular weights of body distributed FTC-CM-chitosan and urinary excreted FTC-CM-chitosan were analyzed by gel chromatography. The results indicated that the FTC-CM-chitosan was degraded in abdominal dropsy. The absorbed CM-chitosan forms were found with a relatively high molecular weight (approximately 300 kDa), whereas the molecular weight of the urinary excreted FTC-CM-chitosan was less than 45 kDa. In vitro research revealed that the CM-Chi was also degradable in plasma and homogenate of liver. The CM-chitosan with a molecular weight of approximately 800k was thoroughly degraded to a small molecule after it was incubated in homogenate of liver at 37 degrees C for 24 h. The results suggested that the liver plays a central role in biodegradation of CM-chitosan. The excellent biodegradability of CM-chitosan could potentially contribute to the clinical applications. The results also provide important clues for further modification of CM-chitosan as the postsurgical and other biomedical materials.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20459052     DOI: 10.1021/bm100158p

Source DB:  PubMed          Journal:  Biomacromolecules        ISSN: 1525-7797            Impact factor:   6.988


  6 in total

1.  Effects of molecular weights on the absorption, distribution and urinary excretion of intraperitoneally administrated carboxymethyl chitosan in rats.

Authors:  Wen Dong; Baoqin Han; Kai Shao; Zhao Yang; Yanfei Peng; Yan Yang; Wanshun Liu
Journal:  J Mater Sci Mater Med       Date:  2012-08-14       Impact factor: 3.896

2.  Acute toxicity of high dosage carboxymethyl chitosan and its effect on the blood parameters in rats.

Authors:  Zhao Yang; Baoqin Han; Dawei Fu; Wanshun Liu
Journal:  J Mater Sci Mater Med       Date:  2011-11-01       Impact factor: 3.896

3.  Influence of the carboxymethyl chitosan anti-adhesion solution on the TGF-β1 in a postoperative peritoneal adhesion rat.

Authors:  Zengjuan Zheng; Weifen Zhang; Weiqing Sun; Xiaojian Li; Jinghua Duan; Juanjuan Cui; Zhanqin Feng; Heidi M Mansour
Journal:  J Mater Sci Mater Med       Date:  2013-07-03       Impact factor: 3.896

4.  Tumor-specific delivery and therapy by double-targeted DTX-CMCS-PEG-NGR conjugates.

Authors:  Fengxi Liu; Min Li; Chunxi Liu; Yongjun Liu; Yanchao Liang; Fengshan Wang; Na Zhang
Journal:  Pharm Res       Date:  2013-09-17       Impact factor: 4.200

Review 5.  Current status of in vivo bioanalysis of nano drug delivery systems.

Authors:  Tingting Wang; Di Zhang; Dong Sun; Jingkai Gu
Journal:  J Pharm Anal       Date:  2020-05-16

6.  Novel Potential Application of Chitosan Oligosaccharide for Attenuation of Renal Cyst Growth in the Treatment of Polycystic Kidney Disease.

Authors:  Nutthapoom Pathomthongtaweechai; Sunhapas Soodvilai; Rath Pichyangkura; Chatchai Muanprasat
Journal:  Molecules       Date:  2020-11-27       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.